M&A

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

News

RayThera founders Qing Dong and Gene Hung

Biogen pens $1bn deal to buy immunology biotech RayThera

Biogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion.

News

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

News

Firefly in a jar illustration on black background

J&J lights up $1bn offer for pan-KRAS developer Firefly

Johnson & Johnson has built its presence in KRAS drugs for cancer with a $1bn deal to buy Firefly Bio and its degrader-antibody conjugate platform.

News

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Incyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.

News

Lilly gets back in infectious disease, via three M&A deals

Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8bn.

AbbVie climbs post-Allergan M&A peak with Apogee buy

Biogen pens $1bn deal to buy immunology biotech RayThera

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

J&J lights up $1bn offer for pan-KRAS developer Firefly

Incyte gobbles up Star's Vega haematology unit in $2bn deal

Lilly gets back in infectious disease, via three M&A deals

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks